Skip to main content
Erschienen in: Rheumatology International 10/2013

01.10.2013 | Original Article

Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis

verfasst von: Seyfi Yıldır, Melek Sezgin, İbrahim Ömer Barlas, Gözde Türköz, Handan Çamdeviren Ankaralı, Günşah Şahin, Mehmet Emin Erdal

Erschienen in: Rheumatology International | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

To investigate associations of the Fas and FasL genes polymorphisms with rheumatoid arthritis (RA). One hundred patients with RA and age-, sex- and ethnically matched 101 controls were included. Four polymorphisms of Fas (-670 A>G rs1800682, -1377 G>A rs2234767) and FasL (IVS2nt-124 A>G rs5030772, -844 T>C rs763110) genes were typed from genomic DNA. Genotype distributions and allelic frequencies were compared between patients and control subjects. After the history and clinical examination of patients with RA, in terms of pain, fatigue and general health status were evaluated by visual analogue scale. Thereafter, erythrocyte sedimentation rate, C-reactive protein, blood count and rheumatoid factor levels were measured. The Disease Activity Score-28, Health Assessment Questionnaire and modified Sharp score were used to evaluate the disease activity, functional disability and radiological damage, and their relationships with the Fas and FasL gene polymorphisms were investigated. In patients with RA, CT and TT genotypes of FasL-844, polymorphism were twofold and 4.8-fold higher, and AA genotype of FasL IVS2nt-124 polymorphism was 3.4-fold higher than the control group (respectively, p = 0.05, p = 0.002, p = 0.039). T allele of FasL-844 polymorphism was more frequent in patients than controls (respectively, 52.5 vs. 41.4 %, p = 0.027). Any association was not detected between Fas (-670 A>G, -1377 G>A) and FasL (-844 T>C, IVS2nt-124 A>G) gene polymorphisms with the disease activity scores, functional disability and radiological damage. However, the Fas-670 A>G polymorphism was associated with drug therapy (p = 0.049). The distribution of GG genotype was higher compared to GA or AA genotypes in patients using triple disease-modifying antirheumatic drug therapy (71.4, 14.3 and 14.3 %, respectively). These findings suggest that the -844 T>C and IVS2nt-124 A>G polymorphisms in the FasL gene related with apoptosis may increase genetic susceptibility to RA in a Turkish population. In addition, the Fas-670 A>G gene polymorphism may be associated with disease progression. There is a need for further studies to clarify the genetic role of apoptosis in RA.
Literatur
1.
Zurück zum Zitat Maini RN, Zvaifler NJ (1994) Rheumatoid arthritis and spondyloarthropathy. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, St Louis, pp 1–4 Maini RN, Zvaifler NJ (1994) Rheumatoid arthritis and spondyloarthropathy. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, St Louis, pp 1–4
2.
Zurück zum Zitat Sumida T, Hasunuma T, Asahara H, Maeda T, Nishioka K (1998) Rheumatoid arthritis and apoptosis. Intern Med 37:184–188PubMedCrossRef Sumida T, Hasunuma T, Asahara H, Maeda T, Nishioka K (1998) Rheumatoid arthritis and apoptosis. Intern Med 37:184–188PubMedCrossRef
3.
Zurück zum Zitat Wakisaka S, Suzuki N, Takeba Y, Shimoyama Y, Nagafuchi H, Takeno M, Saito N, Yokoe T, Kaneko A, Asai T, Sakane T (1998) Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA). Clin Exp Immunol 114:119–128PubMedCrossRef Wakisaka S, Suzuki N, Takeba Y, Shimoyama Y, Nagafuchi H, Takeno M, Saito N, Yokoe T, Kaneko A, Asai T, Sakane T (1998) Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA). Clin Exp Immunol 114:119–128PubMedCrossRef
4.
Zurück zum Zitat Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456–1462PubMedCrossRef Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456–1462PubMedCrossRef
5.
Zurück zum Zitat Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMedCrossRef Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMedCrossRef
6.
7.
Zurück zum Zitat Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M et al (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233–243PubMedCrossRef Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M et al (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233–243PubMedCrossRef
8.
Zurück zum Zitat Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C et al (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267:10709–10715PubMed Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C et al (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267:10709–10715PubMed
9.
Zurück zum Zitat Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T et al (1998) Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 5:331–338PubMedCrossRef Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T et al (1998) Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 5:331–338PubMedCrossRef
10.
Zurück zum Zitat Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K et al (2009) Susceptibility of rheumatoid arthritis synovial fibroblasts to FasLand TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 11(1):R16PubMedCrossRef Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K et al (2009) Susceptibility of rheumatoid arthritis synovial fibroblasts to FasLand TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 11(1):R16PubMedCrossRef
11.
Zurück zum Zitat Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T (1998) Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue. Arthritis Rheum 41:1–9PubMedCrossRef Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T (1998) Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue. Arthritis Rheum 41:1–9PubMedCrossRef
12.
Zurück zum Zitat Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K et al (1995) Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38:485–491PubMedCrossRef Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K et al (1995) Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38:485–491PubMedCrossRef
13.
Zurück zum Zitat Asahara H, Hasumuna T, Kobata T, Yagita H, Okumura K, Inoue H et al (1996) Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 81:27–34PubMedCrossRef Asahara H, Hasumuna T, Kobata T, Yagita H, Okumura K, Inoue H et al (1996) Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 81:27–34PubMedCrossRef
14.
Zurück zum Zitat Firestein GS, Yeo M, Zvaifler NJ (1995) Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96:1631–1638PubMedCrossRef Firestein GS, Yeo M, Zvaifler NJ (1995) Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96:1631–1638PubMedCrossRef
15.
Zurück zum Zitat Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582PubMedCrossRef Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582PubMedCrossRef
16.
Zurück zum Zitat Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL et al (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL et al (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed
17.
Zurück zum Zitat Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC et al (2003) A novel polymorphic CAAT/enhancer-binding protein b element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132–138PubMed Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC et al (2003) A novel polymorphic CAAT/enhancer-binding protein b element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132–138PubMed
18.
Zurück zum Zitat Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347–1349PubMedCrossRef Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347–1349PubMedCrossRef
19.
Zurück zum Zitat Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N (2003) Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 15:167–176PubMedCrossRef Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N (2003) Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 15:167–176PubMedCrossRef
20.
21.
Zurück zum Zitat Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T et al (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6:1567–1574PubMedCrossRef Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T et al (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6:1567–1574PubMedCrossRef
22.
Zurück zum Zitat Singh R, Pradhan V, Patwardhan M, Ghosh K (2009) APO-1/Fas gene: structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases. Indian J Hum Genet 153:98–102 Singh R, Pradhan V, Patwardhan M, Ghosh K (2009) APO-1/Fas gene: structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases. Indian J Hum Genet 153:98–102
23.
Zurück zum Zitat Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 12:3057–3062CrossRef Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 12:3057–3062CrossRef
24.
Zurück zum Zitat Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef
25.
Zurück zum Zitat Fuks A, Parton LA, Polavarapu S, Netta D, Strassberg S, Godi I et al (2005) Polymorphism of Fas and Fas ligand in preterm premature rupture of membranes in singleton pregnancies. Am J Obstet Gynecol 193:1132–1136PubMedCrossRef Fuks A, Parton LA, Polavarapu S, Netta D, Strassberg S, Godi I et al (2005) Polymorphism of Fas and Fas ligand in preterm premature rupture of membranes in singleton pregnancies. Am J Obstet Gynecol 193:1132–1136PubMedCrossRef
26.
Zurück zum Zitat Aguilar-Reina J, Ruiz-Ferrer M, Pizarro MA, Antiñolo G (2005) The -670 A>G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. J Viral Hepat 12:568–573PubMedCrossRef Aguilar-Reina J, Ruiz-Ferrer M, Pizarro MA, Antiñolo G (2005) The -670 A>G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. J Viral Hepat 12:568–573PubMedCrossRef
27.
Zurück zum Zitat Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE et al (2006) Polymorphisms of the FAS and FAS ligand gene associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16:253–263PubMedCrossRef Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE et al (2006) Polymorphisms of the FAS and FAS ligand gene associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16:253–263PubMedCrossRef
28.
Zurück zum Zitat Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P et al (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42:479–484PubMedCrossRef Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P et al (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42:479–484PubMedCrossRef
29.
Zurück zum Zitat Stuck BJ, Pani MA, Besrour F, Segni M, Krause M, Usadel KH et al (2003) Fas ligand gene polymorphisms are not associated with Hashimoto’s thyroiditis and Graves’ disease. Hum Immunol 64:285–289PubMedCrossRef Stuck BJ, Pani MA, Besrour F, Segni M, Krause M, Usadel KH et al (2003) Fas ligand gene polymorphisms are not associated with Hashimoto’s thyroiditis and Graves’ disease. Hum Immunol 64:285–289PubMedCrossRef
30.
Zurück zum Zitat Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphisms of death pathway genesFASand FASL in esophageal squamous cell carcinoma. J Natl Cancer Inst 96:1030–1036PubMedCrossRef Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphisms of death pathway genesFASand FASL in esophageal squamous cell carcinoma. J Natl Cancer Inst 96:1030–1036PubMedCrossRef
31.
Zurück zum Zitat Silman AJ (1997) Problems complicating the genetic epidemiology of rheumatoid arthritis. J Rheumatol 24:194–196PubMed Silman AJ (1997) Problems complicating the genetic epidemiology of rheumatoid arthritis. J Rheumatol 24:194–196PubMed
32.
Zurück zum Zitat Taneja V, Giphart MJ, Verduijn W, Naipal A, Malaviya AN, Mehra NK (1996) Polymorphism of HLA-DRB, -DQA1, and -DQB1 in rheumatoid arthritis in Asian Indians: association with DRB1*0405 and DRB1*1001. Hum Immunol 46:35–41PubMedCrossRef Taneja V, Giphart MJ, Verduijn W, Naipal A, Malaviya AN, Mehra NK (1996) Polymorphism of HLA-DRB, -DQA1, and -DQB1 in rheumatoid arthritis in Asian Indians: association with DRB1*0405 and DRB1*1001. Hum Immunol 46:35–41PubMedCrossRef
33.
Zurück zum Zitat Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903–907PubMedCrossRef Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903–907PubMedCrossRef
34.
Zurück zum Zitat John S, Hajeer A, Marlow A, Myerscough A, Silman AJ, Ollier WE, Worthington J (1997) Investigation of candidate disease susceptibility genes in rheumatoid arthritis: principles and strategies. J Rheumatol 24:199–201PubMed John S, Hajeer A, Marlow A, Myerscough A, Silman AJ, Ollier WE, Worthington J (1997) Investigation of candidate disease susceptibility genes in rheumatoid arthritis: principles and strategies. J Rheumatol 24:199–201PubMed
35.
Zurück zum Zitat Huang QR, Danis V, Lassere M, Edmonds J, Manolios N (1999) Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38:645–651CrossRef Huang QR, Danis V, Lassere M, Edmonds J, Manolios N (1999) Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38:645–651CrossRef
36.
Zurück zum Zitat Mohammadzadeh A, Pourfathollah AA, Tahoori MT, Daneshmandi S, Langroudi L, Akhlaghi M (2011) Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients. Rheumatol Int 31. doi:10.1007/s00296-011-2065-x Mohammadzadeh A, Pourfathollah AA, Tahoori MT, Daneshmandi S, Langroudi L, Akhlaghi M (2011) Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients. Rheumatol Int 31. doi:10.​1007/​s00296-011-2065-x
37.
Zurück zum Zitat Kobak S, Berdeli A (2012) Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis. Reumatismo 64:374–379PubMedCrossRef Kobak S, Berdeli A (2012) Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis. Reumatismo 64:374–379PubMedCrossRef
Metadaten
Titel
Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis
verfasst von
Seyfi Yıldır
Melek Sezgin
İbrahim Ömer Barlas
Gözde Türköz
Handan Çamdeviren Ankaralı
Günşah Şahin
Mehmet Emin Erdal
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 10/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2793-1

Weitere Artikel der Ausgabe 10/2013

Rheumatology International 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.